These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 3086754)

  • 1. [Treatment of advanced prostate carcinoma with a depot form of an LH-RH analog: preliminary endocrinological and clinical results].
    Litjens TT; Fernandez del Moral P; van Laarhoven JP; Weil EH; Debruyne FM
    Ned Tijdschr Geneeskd; 1986 Apr; 130(17):787-90. PubMed ID: 3086754
    [No Abstract]   [Full Text] [Related]  

  • 2. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
    Robinson MR; Denis L; Mahler C; Walker K; Stitch R; Lunglmayr G
    Eur J Surg Oncol; 1985 Jun; 11(2):159-65. PubMed ID: 3159598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma].
    Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Sonoda T
    Hinyokika Kiyo; 1987 Jan; 33(1):141-50. PubMed ID: 2953179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new longer-acting LHRH analog depot: preliminary results of a Dutch open phase II clinical study on a 10.8 mg Zoladex 3-monthly depot.
    Dijkman GA; Fernandez del Moral P; Plasman JW; Pull HC; van der Meijden AP; Debruyne FM; Hutchinson FG; Furr BJ
    Eur Urol; 1990; 18 Suppl 3():22-5. PubMed ID: 2151271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of prostatic cancer with monthly injections of an LH-RH analog].
    Svensson M; Varenhorst E; Hjertberg H; Kågedal B; Nordenskjöld B
    Lakartidningen; 1987 Oct; 84(41):3270-1. PubMed ID: 2960863
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
    Lukkarinen O; Kontturi M
    Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of advanced prostatic carcinoma with a depot LH-RH analog (ICI 118630)].
    Grifoni R; Pierangeli T
    Minerva Urol Nefrol; 1989; 41(1):5-10. PubMed ID: 2527415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical experience with single and multiple subcutaneous administration of LHRH analog Buserelin (Hoe 766) in prostatic carcinoma: endocrinological study of optimum subcutaneous doses].
    Niijima T; Isurugi K; Kawabe K; Kinoshita K; Asano M; Nakauchi K; Fujita K; Nishimura Y; Nitoh H; Yokoyama M
    Hinyokika Kiyo; 1988 Jul; 34(7):1297-307. PubMed ID: 2459944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary report on a phase II multicentric study on depot LH-RH analogue in advanced prostatic cancer.
    Bono AV; Pozzi E; Bianco A; Morelli A; Bolgan A; Albano D; Frugoni A; Usai E
    Prog Clin Biol Res; 1987; 243A():251-3. PubMed ID: 2958856
    [No Abstract]   [Full Text] [Related]  

  • 10. Long term therapy with a depot LHRH analogue (Zoladex) in patients with advanced prostatic cancer.
    Denis L; Keuppens F; Mahler C; Debruyne FM; Weil EH; Lunglmayr G; Newling D; Robinson MR; Richards B; Smith PH
    Prog Clin Biol Res; 1987; 243A():221-7. PubMed ID: 2958852
    [No Abstract]   [Full Text] [Related]  

  • 11. Zoladex treatment of symptomatic prostatic carcinoma.
    Holdaway IM; Ibbertson HK; Croxson MS; Harvey V; Boulton J; Knox BS
    Am J Clin Oncol; 1988; 11 Suppl 2():S123-6. PubMed ID: 2977267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of prostatic cancer with slow-release formulation of luteinizing hormone releasing hormone (LH-RH) analog].
    Fuse H; Akimoto S; Akakura K; Shimazaki J; Murakami S
    Hinyokika Kiyo; 1988 Mar; 34(3):555-60. PubMed ID: 3133936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Endocrine therapy of prostatic carcinoma with slow release (depot) formulation of the LH-RH analog ICI 118630 (Zoladex)].
    Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Akaza H; Isurugi K; Niijima T; Aso Y; Araki T
    Hinyokika Kiyo; 1988 Feb; 34(2):369-82. PubMed ID: 2967622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metastatic prostate cancer under long term pernasal buserelin or intramuscular decapeptyl depot treatment.
    Wenderoth UK; Spindler HW; Ehrenthal W; von Wallenberg H; Happ J; Jacobi GH
    Prog Clin Biol Res; 1987; 243A():207-20. PubMed ID: 2958851
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of prostatic cancer with intranasal administration of LHRH analog, Buserelin (Hoe 766) study of the optimum dosage of intranasal application].
    Niijima T; Kishimoto T; Shimazaki J; Yoshida O; Isurugi K
    Hinyokika Kiyo; 1988 Jul; 34(7):1309-19. PubMed ID: 3140622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [1st clinical results of the treatment of locally advanced prostatic cancer with a powerful LH-RH analog: buserelin acetate].
    Nagel R; Borgmann V; Al-Abadi H; Schmidt-Gollwitzer M
    J Urol (Paris); 1983; 89(9):669-76. PubMed ID: 6425419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and endocrinological parameters of a slow-release depot preparation of the GnRH analogue ICI 118630 (zoladex) compared with a subcutaneous bolus and continuous subcutaneous infusion of the same drug in patients with prostatic cancer.
    Perren TJ; Clayton RN; Blackledge G; Bailey LC; Holder G; Lynch SS; Arkell DG; Cottam J; Farrar D; Young CH
    Cancer Chemother Pharmacol; 1986; 18(1):39-43. PubMed ID: 2944668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The treatment of metastatic prostatic cancer with the slow release LH-RH analogue Zoladex ICI 118630.
    Beacock CJ; Buck AC; Zwinck R; Peeling WB; Rees RW; Turkes A; Walker K; Griffiths K
    Br J Urol; 1987 May; 59(5):436-42. PubMed ID: 2954605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of LH-RH agonists on the growth and hormonal environment of breast and prostate cancer.
    Nicholson RI; Walker KJ
    Chemioterapia; 1985 Jun; 4(3):249-51. PubMed ID: 3161643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biodegradable sustained release formulation of the LH-RH analogue 'Zoladex' for the treatment of hormone-responsive tumours.
    Furr BJ; Hutchinson FG
    Prog Clin Biol Res; 1985; 185A():143-53. PubMed ID: 3162174
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.